Healio Blog: Advancing Classical Hodgkin Lymphoma Care: New ASTCT Recommendations for Transplantation
The treatment landscape for classical Hodgkin lymphoma has evolved rapidly with the introduction of brentuximab vedotin, immune checkpoint inhibitors and other novel therapies.
As treatment options expand, clinicians face important questions regarding the optimal timing of transplantation, the sequencing of therapies, and the role of maintenance and allogeneic transplant strategies.
The American Society for Transplantation and Cellular Therapy (ASTCT) developed updated clinical practice recommendations to help clinicians navigate these decisions. The recommendations — titled “American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma” — have been published in Transplantation and Cellular Therapy.
In this Q&A, lead author Sairah Ahmed, MD, professor in the division of cancer medicine at The University of Texas MD Anderson Cancer Center, discusses the evidence behind the new guidance, key changes in clinical practice, and future directions for improving outcomes among patients with relapsed or refractory disease.